专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07572808B2 Triazolopyridine cannabinoid receptor 1 antagonists 有权
标题翻译：三唑并吡啶大麻素受体1拮抗剂
公开(公告)号：US07572808B2
公开(公告)日：2009-08-11
申请号：US11454322
申请日：2006-06-16
申请人： Chongqing Sun , Philip M. Sher , Gang Wu , William R. Ewing , Yanting Huang , Taekyu Lee , Natesan Murugesan , Richard B. Sulsky
发明人： Chongqing Sun , Philip M. Sher , Gang Wu , William R. Ewing , Yanting Huang , Taekyu Lee , Natesan Murugesan , Richard B. Sulsky
IPC分类号： A61K31/44 , C07D471/02
CPC分类号： C07D471/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物，以及使用式I化合物单独和与一种或多种其他治疗剂。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中本文描述了R1，R2，R3，R4和R5。

2. 发明授权

US07378418B2 Azabicyclic heterocycles as cannabinoid receptor modulators 有权
标题翻译：氮杂环杂环作为大麻素受体调节剂
公开(公告)号：US07378418B2
公开(公告)日：2008-05-27
申请号：US11016135
申请日：2004-12-17
申请人： Guixue Yu , William R. Ewing , Amarendra B. Mikkilineni , Annapurna Pendri , Philip M. Sher , Samuel Gerritz , Bruce A. Ellsworth , Gang Wu , Yanting Huang , Chongqing Sun , Natesan Murugesan , Zhengxiang Gu , Ying Wang , Doree Sitkoff , Stephen R. Johnson , Ximao Wu
发明人： Guixue Yu , William R. Ewing , Amarendra B. Mikkilineni , Annapurna Pendri , Philip M. Sher , Samuel Gerritz , Bruce A. Ellsworth , Gang Wu , Yanting Huang , Chongqing Sun , Natesan Murugesan , Zhengxiang Gu , Ying Wang , Doree Sitkoff , Stephen R. Johnson , Ximao Wu
IPC分类号： C07D487/04 , A61K31/4162 , A61P3/04 , A61P43/00
CPC分类号： C07D487/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法，其单独和与一种或多种另外的治疗剂。该化合物具有通式I：包括所有前药，药学上可接受的盐和立体异构体，R 1，R 2，R 3，R 3，本文描述了SUP 6，R 7，m和n。

3. 发明申请

US20070004772A1 Triazolopyridine cannabinoid receptor 1 antagonists 有权
标题翻译：三唑并吡啶大麻素受体1拮抗剂
公开(公告)号：US20070004772A1
公开(公告)日：2007-01-04
申请号：US11454322
申请日：2006-06-16
申请人： Chongqing Sun , Philip Sher , Gang Wu , William Ewing , Yanting Huang , Taekyu Lee , Natesan Murugesan , Richard Sulsky
发明人： Chongqing Sun , Philip Sher , Gang Wu , William Ewing , Yanting Huang , Taekyu Lee , Natesan Murugesan , Richard Sulsky
IPC分类号： C07D471/02 , A61K31/4745
CPC分类号： C07D471/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物，以及使用式I化合物单独和与一种或多种其他治疗剂。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中R 1，R 2，R 3，本文描述了R 4和R 5。

4. 发明授权

US07276608B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators 有权
标题翻译：四氢喹啉衍生物作为大麻素受体调节剂
公开(公告)号：US07276608B2
公开(公告)日：2007-10-02
申请号：US10889268
申请日：2004-07-12
申请人： Philip M. Sher , Chongqing Sun , Richard B. Sulsky , Gang Wu , William R. Ewing
发明人： Philip M. Sher , Chongqing Sun , Richard B. Sulsky , Gang Wu , William R. Ewing
IPC分类号： C07D215/38
CPC分类号： C07D417/06 , C07D215/38 , C07D215/48 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.
摘要翻译：本发明提供式I化合物，其中取代基如本文所述。还提供了使用这些化合物治疗进食障碍，代谢紊乱，肥胖症，认知障碍，神经障碍，疼痛障碍，炎症障碍，促进戒烟和治疗其他精神疾病的方法。还提供含有这些化合物的药物组合物和本发明化合物与其它治疗剂的药物组合。

5. 发明申请

US20050143381A1 Azabicyclic heterocycles as cannabinoid receptor modulators 有权
标题翻译：氮杂环杂环作为大麻素受体调节剂
公开(公告)号：US20050143381A1
公开(公告)日：2005-06-30
申请号：US11016135
申请日：2004-12-17
申请人： Guixue Yu , William Ewing , Amarendra Mikkilineni , Annapurna Pendri , Philip Sher , Samuel Gerritz , Bruce Ellsworth , Gang Wu , Yanting Huang , Chongqing Sun , Natesan Murugesan , Zhengxiang Gu , Ying Wang , Doree Sitkoff , Stephen Johnson , Ximao Wu
发明人： Guixue Yu , William Ewing , Amarendra Mikkilineni , Annapurna Pendri , Philip Sher , Samuel Gerritz , Bruce Ellsworth , Gang Wu , Yanting Huang , Chongqing Sun , Natesan Murugesan , Zhengxiang Gu , Ying Wang , Doree Sitkoff , Stephen Johnson , Ximao Wu
IPC分类号： A61K31/5025 , C07D487/04 , A61K31/503
CPC分类号： C07D487/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法，其单独和与一种或多种另外的治疗剂。该化合物具有通式I：包括所有前药，药学上可接受的盐和立体异构体，R 1，R 2，R 3，R 3，本文描述了SUP 6，R 7，m和n。

6. 发明授权

US07452892B2 Triazolopyrimidine cannabinoid receptor 1 antagonists 有权
标题翻译：三唑并嘧啶大麻素受体1拮抗剂
公开(公告)号：US07452892B2
公开(公告)日：2008-11-18
申请号：US11455083
申请日：2006-06-16
申请人： Gang Wu , Amarendra B. Mikkilineni , Philip M. Sher , Natesan Murugesan , Zhengxiang Gu
发明人： Gang Wu , Amarendra B. Mikkilineni , Philip M. Sher , Natesan Murugesan , Zhengxiang Gu
IPC分类号： A61K31/519 , A01N43/90 , C07D487/00
CPC分类号： C07D487/04
摘要： The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.
摘要翻译：本申请描述了根据式I和II的化合物，包含至少一种式I或II的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I和II的化合物的治疗方法单独并与一种或多种另外的治疗剂组合。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中R 1，R 2，R 3，本文描述了R 4和R 5。

7. 发明授权

US07517991B2 N-sulfonylpiperidine cannabinoid receptor 1 antagonists 有权
标题翻译： N-磺酰基哌啶大麻素受体1拮抗剂
公开(公告)号：US07517991B2
公开(公告)日：2009-04-14
申请号：US11247492
申请日：2005-10-11
申请人： Philip M. Sher , Gang Wu , William R. Ewing
发明人： Philip M. Sher , Gang Wu , William R. Ewing
IPC分类号： C07D211/06 , A61K31/445
CPC分类号： C07D401/12 , C07D211/96 , C07D409/12
摘要： The present application describes compounds according to Formula I, wherein R1, R2, R3, R4, X and Y are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents.
摘要翻译：本申请描述了根据式I的化合物，其中本文描述了R 1，R 2，R 3，R 4，X和Y。另外，本申请描述了药物组合物，其包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂。最后，本申请描述了单独使用式I化合物和与一种或多种另外的治疗剂组合的治疗方法。

8. 发明申请

US20060287341A1 Triazolopyrimidine cannabinoid receptor 1 antagonists 有权
标题翻译：三唑并嘧啶大麻素受体1拮抗剂
公开(公告)号：US20060287341A1
公开(公告)日：2006-12-21
申请号：US11455083
申请日：2006-06-16
申请人： Gang Wu , Amarendra Mikkilineni , Philip Sher , Natesan Murugesan , Zhengxiang Gu
发明人： Gang Wu , Amarendra Mikkilineni , Philip Sher , Natesan Murugesan , Zhengxiang Gu
IPC分类号： A61K31/519 , C07D487/04
CPC分类号： C07D487/04
摘要： The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.
摘要翻译：本申请描述了根据式I和II的化合物，包含至少一种式I或II的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I和II的化合物的治疗方法单独并与一种或多种另外的治疗剂组合。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中R 1，R 2，R 3，本文描述了R 4和R 5。

9. 发明授权

US07214704B2 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors 有权
标题翻译： 2-氨基-1-官能化的四氢化萘衍生物和相关的糖原磷酸化酶抑制剂
公开(公告)号：US07214704B2
公开(公告)日：2007-05-08
申请号：US11273445
申请日：2005-11-14
申请人： Gang Wu , Philip M. Sher
发明人： Gang Wu , Philip M. Sher
IPC分类号： A61K31/405 , C07D209/12 , C07D209/14
CPC分类号： C07D235/24 , C07D209/42 , C07D401/12 , C07D403/12 , C07D491/04 , C07D495/04
摘要： Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R1, R2, Y and Z are defined herein.
摘要翻译：提供了新型化合物，其是可用于治疗，预防或减缓需要糖原磷酸化酶抑制剂治疗（如糖尿病和相关病症（如高血糖，葡萄糖耐量异常，胰岛素抵抗和高胰岛素血症））的疾病进展的糖原磷酸化酶抑制剂，微血管与糖尿病相关的并发症（如视网膜病变，神经病变，肾病和延迟伤口愈合），与糖尿病相关的大血管并发症（心血管疾病如动脉粥样硬化，心脏功能异常，心肌缺血和中风）以及代谢综合征及其组成条件包括高血压，肥胖和血脂异常（包括高甘油三酯血症，高胆固醇血症和低HDL）以及其他疾病如非心脏缺血，感染和癌症。这些新化合物具有其结构或立体异构体或前药或其药学上可接受的盐，其中W，R 1，R 2，Y和Z在本文中定义。

10. 发明授权

US06936590B2 C-aryl glucoside SGLT2 inhibitors and method 有权
标题翻译： C-芳基葡糖苷SGLT2抑制剂及方法
公开(公告)号：US06936590B2
公开(公告)日：2005-08-30
申请号：US10264410
申请日：2002-10-04
申请人： William N. Washburn , Bruce Ellsworth , Wei Meng , Gang Wu , Philip M. Sher
发明人： William N. Washburn , Bruce Ellsworth , Wei Meng , Gang Wu , Philip M. Sher
IPC分类号： A61K31/70 , A61K31/7052 , A61K45/06
CPC分类号： A61K45/06 , A61K31/70 , A61K31/7052 , A61K2300/00
摘要： A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).
摘要翻译：提供了一种用于治疗糖尿病和相关疾病的方法，其使用抑制SGLT2的量的单独的化合物或与一种或多种其它抗糖尿病剂或其它治疗剂组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式